Characteristics of oral mucosal events related to bevacizumab treatment

Igor T. Gavrilovic, Yevgeniy Balagula, Alyx C. Rosen, Vijay Ramaswamy, Maura N. Dickler, Ira J. Dunkel, Mario E. Lacouture

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background. Bevacizumab, a monoclonal antibody targeting a vascular endothelial growth factor (VEGF) protein, has been reported to induce mucosal toxicities. However, the clinical characteristics of these particular toxicities have not been well characterized. We aimed at providing a detailed clinical description of signs and symptoms limited to the tongue mucosa in patients treated with bevacizumab. Methods. A retrospective review of medical records and clinical photographs was performed with specific attention to clinical presentation, evolution, associated symptoms, concomitant medications, and treatment methods. Results. In total, four patients presented to the dermatology service with clinical findings characterized by multifocal, erythematous circinate and serpiginous erosions on the dorsal tongue surrounded by white hyperkeratotic rims that were temporally related to bevacizumab therapy. Associated increased sensitivity to spicy foods was frequently observed. Conclusion. These characteristic clinical findings are consistent with geographic tongue. However, large prospective evaluations are necessary to confirm this potential relationship. If bevacizumab is indeed associated with geographic tongue, increased awareness may result in improved reporting and characterization of this particular adverse event.

Original languageEnglish (US)
Pages (from-to)274-278
Number of pages5
JournalOncologist
Volume17
Issue number2
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Benign Migratory Glossitis
Tongue
Therapeutics
Dermatology
Vascular Endothelial Growth Factor A
Signs and Symptoms
Medical Records
Mucous Membrane
Monoclonal Antibodies
Food
Bevacizumab
Proteins

Keywords

  • Bevacizumab mucosal toxicity adverse event geographic tongue

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gavrilovic, I. T., Balagula, Y., Rosen, A. C., Ramaswamy, V., Dickler, M. N., Dunkel, I. J., & Lacouture, M. E. (2012). Characteristics of oral mucosal events related to bevacizumab treatment. Oncologist, 17(2), 274-278. https://doi.org/10.1634/theoncologist.2011-0198

Characteristics of oral mucosal events related to bevacizumab treatment. / Gavrilovic, Igor T.; Balagula, Yevgeniy; Rosen, Alyx C.; Ramaswamy, Vijay; Dickler, Maura N.; Dunkel, Ira J.; Lacouture, Mario E.

In: Oncologist, Vol. 17, No. 2, 2012, p. 274-278.

Research output: Contribution to journalArticle

Gavrilovic, IT, Balagula, Y, Rosen, AC, Ramaswamy, V, Dickler, MN, Dunkel, IJ & Lacouture, ME 2012, 'Characteristics of oral mucosal events related to bevacizumab treatment', Oncologist, vol. 17, no. 2, pp. 274-278. https://doi.org/10.1634/theoncologist.2011-0198
Gavrilovic, Igor T. ; Balagula, Yevgeniy ; Rosen, Alyx C. ; Ramaswamy, Vijay ; Dickler, Maura N. ; Dunkel, Ira J. ; Lacouture, Mario E. / Characteristics of oral mucosal events related to bevacizumab treatment. In: Oncologist. 2012 ; Vol. 17, No. 2. pp. 274-278.
@article{a10a2986c86d4d61a17bc6dce0e00064,
title = "Characteristics of oral mucosal events related to bevacizumab treatment",
abstract = "Background. Bevacizumab, a monoclonal antibody targeting a vascular endothelial growth factor (VEGF) protein, has been reported to induce mucosal toxicities. However, the clinical characteristics of these particular toxicities have not been well characterized. We aimed at providing a detailed clinical description of signs and symptoms limited to the tongue mucosa in patients treated with bevacizumab. Methods. A retrospective review of medical records and clinical photographs was performed with specific attention to clinical presentation, evolution, associated symptoms, concomitant medications, and treatment methods. Results. In total, four patients presented to the dermatology service with clinical findings characterized by multifocal, erythematous circinate and serpiginous erosions on the dorsal tongue surrounded by white hyperkeratotic rims that were temporally related to bevacizumab therapy. Associated increased sensitivity to spicy foods was frequently observed. Conclusion. These characteristic clinical findings are consistent with geographic tongue. However, large prospective evaluations are necessary to confirm this potential relationship. If bevacizumab is indeed associated with geographic tongue, increased awareness may result in improved reporting and characterization of this particular adverse event.",
keywords = "Bevacizumab mucosal toxicity adverse event geographic tongue",
author = "Gavrilovic, {Igor T.} and Yevgeniy Balagula and Rosen, {Alyx C.} and Vijay Ramaswamy and Dickler, {Maura N.} and Dunkel, {Ira J.} and Lacouture, {Mario E.}",
year = "2012",
doi = "10.1634/theoncologist.2011-0198",
language = "English (US)",
volume = "17",
pages = "274--278",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "2",

}

TY - JOUR

T1 - Characteristics of oral mucosal events related to bevacizumab treatment

AU - Gavrilovic, Igor T.

AU - Balagula, Yevgeniy

AU - Rosen, Alyx C.

AU - Ramaswamy, Vijay

AU - Dickler, Maura N.

AU - Dunkel, Ira J.

AU - Lacouture, Mario E.

PY - 2012

Y1 - 2012

N2 - Background. Bevacizumab, a monoclonal antibody targeting a vascular endothelial growth factor (VEGF) protein, has been reported to induce mucosal toxicities. However, the clinical characteristics of these particular toxicities have not been well characterized. We aimed at providing a detailed clinical description of signs and symptoms limited to the tongue mucosa in patients treated with bevacizumab. Methods. A retrospective review of medical records and clinical photographs was performed with specific attention to clinical presentation, evolution, associated symptoms, concomitant medications, and treatment methods. Results. In total, four patients presented to the dermatology service with clinical findings characterized by multifocal, erythematous circinate and serpiginous erosions on the dorsal tongue surrounded by white hyperkeratotic rims that were temporally related to bevacizumab therapy. Associated increased sensitivity to spicy foods was frequently observed. Conclusion. These characteristic clinical findings are consistent with geographic tongue. However, large prospective evaluations are necessary to confirm this potential relationship. If bevacizumab is indeed associated with geographic tongue, increased awareness may result in improved reporting and characterization of this particular adverse event.

AB - Background. Bevacizumab, a monoclonal antibody targeting a vascular endothelial growth factor (VEGF) protein, has been reported to induce mucosal toxicities. However, the clinical characteristics of these particular toxicities have not been well characterized. We aimed at providing a detailed clinical description of signs and symptoms limited to the tongue mucosa in patients treated with bevacizumab. Methods. A retrospective review of medical records and clinical photographs was performed with specific attention to clinical presentation, evolution, associated symptoms, concomitant medications, and treatment methods. Results. In total, four patients presented to the dermatology service with clinical findings characterized by multifocal, erythematous circinate and serpiginous erosions on the dorsal tongue surrounded by white hyperkeratotic rims that were temporally related to bevacizumab therapy. Associated increased sensitivity to spicy foods was frequently observed. Conclusion. These characteristic clinical findings are consistent with geographic tongue. However, large prospective evaluations are necessary to confirm this potential relationship. If bevacizumab is indeed associated with geographic tongue, increased awareness may result in improved reporting and characterization of this particular adverse event.

KW - Bevacizumab mucosal toxicity adverse event geographic tongue

UR - http://www.scopus.com/inward/record.url?scp=84857417613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857417613&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2011-0198

DO - 10.1634/theoncologist.2011-0198

M3 - Article

C2 - 22282905

AN - SCOPUS:84857417613

VL - 17

SP - 274

EP - 278

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 2

ER -